Ivosidenib
Overview
Ivosidenib is an oral small-molecule targeted therapy that selectively inhibits mutated isocitrate dehydrogenase-1 (IDH1) enzymes. Mutations in IDH1 lead to abnormal production of the oncometabolite 2-hydroxyglutarate, which interferes with normal cellular differentiation and contributes to malignant transformation. By inhibiting the mutant IDH1 enzyme, ivosidenib reduces 2-hydroxyglutarate levels and promotes differentiation of malignant cells. It is administered orally and is used in adults with certain IDH1-mutated hematologic and solid malignancies confirmed by validated diagnostic testing. Ivosidenib represents a precision oncology therapy, as its use is restricted to patients whose tumors harbor susceptible IDH1 mutations. Its clinical importance lies in providing a targeted treatment option for patients with limited alternatives, particularly in relapsed, refractory, or molecularly defined disease settings.
Background and Date of Approval
Ivosidenib was approved by the United States Food and Drug Administration on July 20, 2018, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. On May 2, 2019, the FDA expanded approval to include newly diagnosed AML with an IDH1 mutation in adults aged 75 years or older or those with comorbidities precluding intensive induction chemotherapy. On August 25, 2021, the FDA approved ivosidenib for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. Ivosidenib received marketing authorisation in the European Union in May 2023 for adults with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after at least one prior line of systemic therapy. These approvals were supported by clinical trial data demonstrating response rates and progression-free survival benefit in molecularly selected populations.
Uses
Ivosidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation, as well as for newly diagnosed IDH1-mutated AML in patients who are not candidates for intensive chemotherapy. It is also indicated for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. Use requires confirmation of the mutation through validated molecular testing prior to initiation.
Administration
Ivosidenib is administered orally at a recommended dose of 500 milligrams once daily, taken with or without food, continued until disease progression or unacceptable toxicity. Tablets should be swallowed whole and not crushed or split. Dose modifications or temporary interruptions may be required for adverse reactions such as differentiation syndrome, QT interval prolongation, or other significant toxicities. Regular clinical and laboratory monitoring is required throughout treatment to guide dosing decisions and ensure patient safety.
Side Effects
Common side effects associated with ivosidenib include fatigue, nausea, diarrhea, abdominal pain, decreased appetite, leukocytosis, anemia, arthralgia, and electrolyte abnormalities. In patients with AML, differentiation syndrome and leukocytosis are notable events requiring prompt recognition and management. The frequency and severity of side effects vary among individuals and are often manageable with supportive care or dose adjustment under medical supervision.
Warnings
Serious adverse reactions include differentiation syndrome, which can be life-threatening if not promptly treated, QT interval prolongation that may increase the risk of arrhythmias, and Guillain-Barré syndrome. Hepatotoxicity and severe leukocytosis may also occur. Patients should be closely monitored for signs of differentiation syndrome such as fever, dyspnea, pulmonary infiltrates, and rapid weight gain, and treatment should be interrupted with initiation of corticosteroids if suspected. Ivosidenib may cause embryo-fetal harm and should not be used during pregnancy; effective contraception is recommended during treatment and for a defined period afterward.
Precautions
Baseline assessments should include electrocardiogram evaluation, serum electrolytes, and liver function tests prior to initiating therapy. Periodic ECG monitoring is recommended due to the risk of QT prolongation. Ivosidenib is metabolized primarily via CYP3A4, and concomitant use of strong CYP3A4 inhibitors or inducers may alter drug exposure, requiring careful clinical evaluation and possible dose adjustment. Caution is advised in patients with pre-existing cardiac conditions or electrolyte disturbances. Live vaccines should generally be avoided during treatment due to potential immunologic effects.
Expert Tips
Patient selection for ivosidenib must be based on confirmed presence of a susceptible IDH1 mutation using validated molecular diagnostics. Baseline ECG, electrolyte correction, and comprehensive laboratory evaluation should be completed prior to initiation. Educate patients about symptoms of differentiation syndrome and the importance of immediate reporting of respiratory symptoms, rapid weight gain, or fever. Pharmacists should review concomitant medications for CYP3A4 interactions, ensure appropriate dosing, and reinforce adherence to once-daily oral therapy. Coordination with oncology teams is essential to integrate ivosidenib appropriately within individualized treatment plans and to monitor for early signs of serious toxicity.